Article

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany.
Annals of the rheumatic diseases (Impact Factor: 9.27). 06/2011; 70(6):896-904. DOI: 10.1136/ard.2011.151027
Source: PubMed

ABSTRACT This first update of the ASAS/EULAR recommendations on the management of ankylosing spondylitis (AS) is based on the original paper, a systematic review of existing recommendations and the literature since 2005 and the discussion and agreement among 21 international experts, 2 patients and 2 physiotherapists in a meeting in February 2010. Each original bullet point was discussed in detail and reworded if necessary. Decisions on new recommendations were made - if necessary after voting. The strength of the recommendations (SOR) was scored on an 11-point numerical rating scale after the meeting by email. These recommendations apply to patients of all ages that fulfill the modified NY criteria for AS, independent of extra-articular manifestations, and they take into account all drug and non-drug interventions related to AS. Four overarching principles were introduced, implying that one bullet has been moved to this section. There are now 11 bullet points including 2 new ones, one related to extra-articular manifestations and one to changes in the disease course. With a mean score of 9.1 (range 8-10) the SOR was generally very good.

Full-text

Available from: Ewa Stanislawska-Biernat, Jun 12, 2015
1 Follower
 · 
298 Views
  • Cochrane Database of Systematic Reviews, 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Glucocorticoids (GCs) have been an invaluable tool in the treatment of patients with rheumatic diseases. The aims of GC therapy vary for different indications from symptom management to disease-modification and immunmodulation. Even after 60 years of GC use, there is still a lack of knowledge concerning optimal therapeutic strategies with GCs. Taking this into account, optimal dosage schedules for inflammatory rheumatic diseases are discussed.
    DMW - Deutsche Medizinische Wochenschrift 09/2012; 137(36):1751-4. DOI:10.1055/s-0032-1305218 · 0.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucocorticoids remain part of the treatment strategy in many rheumatic diseases, because of their anti-inflammatory and immunosuppressive actions. Unfortunately, their clinically desired effects are linked to adverse effects, especially at higher dosages and longer duration of treatment. In this review, we describe new insights into the mechanisms of anti-inflammatory glucocorticoid actions and provide an update on recent approaches to improve the risk/benefit ratio of glucocorticoid therapy. Improved knowledge of the immunomodulatory role of endogenous glucocorticoids has evolved, and we report on the therapeutic potential of targeting glucocorticoid pre-receptor metabolism for metabolic and inflammatory diseases.
    Best practice & research. Clinical rheumatology 12/2011; 25(6):891-900. DOI:10.1016/j.berh.2011.11.002 · 3.06 Impact Factor